PDF
ePub
Citation
Print
Abstract
Purpose
To investigate the clinical characteristics and treatment of intermediate uveitis under new diagnostic standards. Methods: Medical records of patients diagnosed with pars planitis or intermediate uveitis were followed for more than 6 months, and retrospectively reviewed.
Results
A total of 90 patients and 117 eyes were enrolled in the study. The mean age was 40.1 years, and the mean follow-up period was 43.0 months. Thirty percent of cases were bilateral. The most common initial symptom was decreased visual acuity. Snowbank was detected in 39.3%, snowballs in 15.4%, vitritis in 96.6%, and vasculitis in 56.4%. Common complications includedcystoid macular edema (57.3%), cataracts (43.6%), and epiretinal membrane (36.8%). Therapies included topical steroids (82.9% of cases), posterior sub-Tenon steroid injection (45.3% of cases), systemic steroid administration (67.8% of cases), and immunosuppressants (28.7% of cases). Vitrectomy was performed in 11.1% of patients due to complications such as epiretinal membrane and traction retinal detachment. The mean initial and final visual acuities were 0.67 and 0.74, respectively.
Go to : 
References
1. The standardization of Uveitis Nomenclature (SUN) working group Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140:509–16.
2. Vitale AT, Zierhut M, Foster CS. Diagnosis and treatment of uveitis. Philadelphia: WB Saunders Company;2001. p. 844–57.
3. Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis. Semin Ophthalmol. 2005; 20:147–54.
4. Park IW, Chung H. Clinical analysis of peripheral uveitis. J Korean Ophthalmol Soc. 1989; 30:535–41.
5. Park JW, Cho HJ, Seo MS. Clinical analysis of pars planitis with promeinent snowbank. J Korean Ophthalmol Soc. 2002; 43:509–15.
6. Park WC, Chung H. Clinical analysis of intermediate uveitis. J Korean Ophthalmol Soc. 2003; 44:344–50.
7. Smith RE, Godfrey WA, Kimura SJ. Chronic cyclitis. I. Course and visual prognosis. Trans Am Acad Ophthalmol Otolaryngol. 1973; 77:760–8.
8. Palimeris G, Marcomichelakis N, Konstantinidou V, Trak-aniari AN. Intermediate uveitis: What is the natural course of the disease and its relationship with other systemic disease? Eur J Ophthalmol. 1994; 4:223–7.
9. Lai WW, Pulido JS. Intermediate uveitis. Ophthalmol Clin North Am. 2002; 15:309–17.
10. Donaldson MJ, Pulido JS, Herman DC. . Pars planitis: A 20-Year Study of Incidence, Clinical Features, and Outcomes. Am J Ophthalmol. 2007; 144:812–7.
11. Lauer AK, Smith JR, Robertson JE, Rosenbaum JT. Vitreous hemorrhage is a common complication of pediatric pars planitis. Ophthalmology. 2002; 109:95–8.
12. Henderly DE, Genstler AJ, Rao NA, Smith RE. Pars planitis. Trans Ophthalmol Soc U K. 1986; 105:227–32.
13. Raja SC, Jabs DA, Dunn JP. . Pars planitis: Clinical features and class II HLA associations. Ophthalmology. 1999; 106:594–9.
14. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993; 100:818–24.
15. Guest S, Funkhouser E, Lightman S. Pars planitis: A com-parison of childhood onset and adult onset disease. Clin Experiment Ophthalmol. 2001; 29:81–4.
16. Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol. 2007; 18:212–9.
17. Schlagel TF Jr, Weber JC. Treatment of pars planitis, II corticosteroids. Surv Ophthalmol. 1977; 22:120. 125–30.
Go to :
Table 1.
Distribution of age
| Age | No. of patients (%) |
|---|---|
| < 10 | 3 (3.3) |
| 10~19 | 4 (4.4) |
| 20~29 | 9 (10.0) |
| 30~39 | 26 (28.9) |
| 40~49 | 30 (33.3) |
| 50~59 | 10 (11.1) |
| ≥ 60 | 8 (8.9) |
| Total | 90 (100) |
Table 2.
Follow-up periods
| Period 6M~1Y | Cases (%) 16 (13.7) |
|---|---|
| 1~2Y | 27 (23.1) |
| 2~4Y | 34 (29.1) |
| 4~8Y | 32 (27.4) |
| > 8Y | 8 (6.8) |
| Total | 117 (100) |
Table 3.
Duration of disease at the first visit
| Period | Cases (%) |
|---|---|
| <1M | 36 (30.8) |
| 1~6M | 31 (26.5) |
| 6~12M | 11 (9.4) |
| 1~2Y | 11 (9.4) |
| 2~4Y | 14 (12.0) |
| > 4Y | 14 (12.0) |
| Total | 117 (100) |
Table 4.
Initial symptoms
| Symptom | Cases (%) |
|---|---|
| Decreased visual acuity | 69 (59.0) |
| Floater | 20 (17.1) |
| Injection | 11 (9.4) |
| Discomfort | 7 (6.0) |
| Ocular pain | 4 (3.4) |
| Metamorphopsia | 1 (0.9) |
| No symptom | 11 (9.4) |
Table 5.
Location of snowbank
| Location | Cases (%) |
|---|---|
| Superior | 34 (77.3) |
| Inferior | 10 (22.7) |
| Superior and Inferior | 4 (9.1) |
| Others | 4 (9.1) |
Table 6.
Ocular findings and complications
Table 7.
Treatments
XML Download